

Peter Sandercock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1669313/publications.pdf>

Version: 2024-02-01

116
papers

12,810
citations

61857

43
h-index

24179

110
g-index

118
all docs

118
docs citations

118
times ranked

15105
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors influencing the use of different methods of consent in a randomized acute stroke trial: The Third International Stroke Trial (IST-3). <i>International Journal of Stroke</i> , 2022, 17, 553-558.	2.9	5
2	Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke. <i>Stroke and Vascular Neurology</i> , 2021, 6, 238-243.	1.5	6
3	Conceptual framework for establishing the African Stroke Organization. <i>International Journal of Stroke</i> , 2021, 16, 93-99.	2.9	20
4	Feasibility and diagnostic accuracy of using brain attenuation changes on CT to estimate time of ischemic stroke onset. <i>Neuroradiology</i> , 2021, 63, 869-878.	1.1	10
5	Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial. <i>European Stroke Journal</i> , 2021, 6, 222-228.	2.7	45
6	In Memoriam Eivind Berge, MD, PhD, 1964–2020. <i>European Stroke Journal</i> , 2020, 5, 113-114.	2.7	0
7	In memoriam Eivind Berge, MD, PhD, 1964–2020: cardiologist, trialist and hypertension/stroke researcher. <i>Journal of Hypertension</i> , 2020, 38, 1199-1200.	0.3	0
8	Eivind Berge, MD, PhD, 1964–2020. <i>Stroke</i> , 2020, 51, 1353-1355.	1.0	1
9	Improving Clinical Detection of Acute Lacunar Stroke. <i>Stroke</i> , 2020, 51, 1411-1418.	1.0	11
10	Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-94.	1.3	10
11	Fluoxetine and Fractures After Stroke. <i>Stroke</i> , 2019, 50, 3280-3282.	1.0	5
12	How can the World Stroke Organization (WSO) optimize education in stroke medicine around the world? Report of the 2018 WSO Global Stroke Stakeholder Workshop. <i>International Journal of Stroke</i> , 2019, 14, 803-805.	2.9	7
13	Top 10 global educational topics in stroke: A survey by the World Stroke Organization. <i>International Journal of Stroke</i> , 2019, 14, 843-849.	2.9	5
14	Clinical diagnosis of TIA or minor stroke and prognosis in patients with neurological symptoms: A rapid access clinic cohort. <i>PLoS ONE</i> , 2019, 14, e0210452.	1.1	7
15	Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. <i>Lancet</i> , 2019, 393, 877-888.	6.3	178
16	Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. <i>Lancet</i> , 2019, 393, 265-274.	6.3	213
17	Cut stroke in half: Polypill for primary prevention in stroke. <i>International Journal of Stroke</i> , 2018, 13, 633-647.	2.9	29
18	How to do high-quality clinical research 1: First steps. <i>International Journal of Stroke</i> , 2018, 13, 121-128.	2.9	4

#	ARTICLE	IF	CITATIONS
19	Blood pressure variability and leukoaraiosis in acute ischemic stroke. <i>International Journal of Stroke</i> , 2018, 13, 473-480.	2.9	5
20	World Stroke Day – a day of global action. <i>International Journal of Stroke</i> , 2018, 13, 779-779.	2.9	1
21	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. <i>International Journal of Stroke</i> , 2018, 13, 175-189.	2.9	36
22	Increasing value and reducing waste in stroke research. <i>Lancet Neurology</i> , The, 2017, 16, 399-408.	4.9	33
23	IST-3 stroke trial data available. <i>Lancet</i> , The, 2016, 387, 1904.	6.3	5
24	European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke. <i>European Stroke Journal</i> , 2016, 1, 6-19.	2.7	39
25	Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial). <i>Stroke</i> , 2016, 47, 2959-2965.	1.0	25
26	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. <i>Lancet Neurology</i> , The, 2016, 15, 925-933.	4.9	187
27	Which stroke patients gain most from intermittent pneumatic compression: further analyses of the CLOTS 3 trial. <i>International Journal of Stroke</i> , 2015, 10, 103-107.	2.9	4
28	Review and prioritization of stroke research recommendations to address the mission of the World Stroke Organization: a call to action from the WSO Research Committee. <i>International Journal of Stroke</i> , 2015, 10, 4-9.	2.9	14
29	New Strategy to Reduce the Global Burden of Stroke. <i>Stroke</i> , 2015, 46, 1740-1747.	1.0	71
30	Influence of Intracerebral Hemorrhage Location on Incidence, Characteristics, and Outcome. <i>Stroke</i> , 2015, 46, 361-368.	1.0	142
31	Effects of Blood Pressure and Blood Pressure-Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke. <i>Stroke</i> , 2015, 46, 3362-3369.	1.0	83
32	Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3. <i>Stroke</i> , 2015, 46, 2325-2327.	1.0	44
33	Sensitivity and Specificity of the Hyperdense Artery Sign for Arterial Obstruction in Acute Ischemic Stroke. <i>Stroke</i> , 2015, 46, 102-107.	1.0	106
34	The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. <i>Health Technology Assessment</i> , 2015, 19, 1-90.	1.3	56
35	Targeting Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Based on Risk of Intracranial Hemorrhage or Poor Functional Outcome. <i>Stroke</i> , 2014, 45, 1000-1006.	1.0	64
36	Effect of Alteplase Within 6 Hours of Acute Ischemic Stroke on All-Cause Mortality (Third) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td (l	1.0	17

#	ARTICLE	IF	CITATIONS
37	Third International Stroke Trial 3. <i>Current Opinion in Neurology</i> , 2014, 27, 8-12.	1.8	3
38	Is the 'liberation procedure' for multiple sclerosis really liberating?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 362-362.	0.9	1
39	Functional Status Three Months after the First Ischemic Stroke Is Associated with Long-Term Outcome: Data from a Community-Based Cohort. <i>Cerebrovascular Diseases</i> , 2014, 38, 46-54.	0.8	40
40	Length of Carotid Stenosis Predicts Peri-Procedural Stroke or Death and Restenosis in Patients Randomized to Endovascular Treatment or Endarterectomy. <i>International Journal of Stroke</i> , 2014, 9, 297-305.	2.9	49
41	Alteplase for ischaemic stroke – responses. <i>Lancet, The</i> , 2014, 384, 660-661.	6.3	2
42	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. <i>Lancet, The</i> , 2014, 384, 1929-1935.	6.3	1,971
43	An assessment of the cost-effectiveness of magnetic resonance, including diffusion-weighted imaging, in patients with transient ischaemic attack and minor stroke: a systematic review, meta-analysis and economic evaluation. <i>Health Technology Assessment</i> , 2014, 18, 1-368.	1.3	63
44	Does intermittent pneumatic compression reduce the risk of post stroke deep vein thrombosis? The CLOTS 3 trial: statistical analysis plan. <i>Trials</i> , 2013, 14, 66.	0.7	9
45	Intermittent pneumatic compression in patients with stroke – Authors' reply. <i>Lancet, The</i> , 2013, 382, 1481-1482.	6.3	23
46	The Effect of Graduated Compression Stockings on Long-term Outcomes After Stroke. <i>Stroke</i> , 2013, 44, 1075-1079.	1.0	35
47	Why Calls for More Routine Carotid Stenting Are Currently Inappropriate. <i>Stroke</i> , 2013, 44, 1186-1190.	1.0	46
48	Clinical and imaging services for TIA and minor stroke: results of two surveys of practice across the UK. <i>BMJ Open</i> , 2013, 3, e003359.	0.8	26
49	Why the United States Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting. <i>Vascular</i> , 2012, 20, 1-7.	0.4	2
50	Why the US Center for Medicare and Medicaid Services Should Not Extend Reimbursement Indications for Carotid Artery Angioplasty/Stenting. <i>Angiology</i> , 2012, 63, 639-644.	0.8	4
51	The Use of Blood Biomarkers to Predict Poor Outcome After Acute Transient Ischemic Attack or Ischemic Stroke. <i>Stroke</i> , 2012, 43, 86-91.	1.0	111
52	Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. <i>Lancet, The</i> , 2012, 379, 2364-2372.	6.3	847
53	The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. <i>Lancet, The</i> , 2012, 379, 2352-2363.	6.3	1,018
54	Thrombolysis in acute ischaemic stroke – Authors' reply. <i>Lancet, The</i> , 2012, 380, 1054-1055.	6.3	1

#	ARTICLE	IF	CITATIONS
55	Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator. <i>Stroke</i> , 2012, 43, 2904-2909.	1.0	259
56	Why the United States Center for Medicare and Medicaid Services (CMS) should not extend reimbursement indications for carotid artery angioplasty/stenting. <i>Brain and Behavior</i> , 2012, 2, 200-207.	1.0	4
57	Negative Results: Why Do they Need to be Published?. <i>International Journal of Stroke</i> , 2012, 7, 32-33.	2.9	32
58	Statistical Analysis Plan for the Third International Stroke Trial (IST-3); Part of a "Thread" of Reports of the Trial. <i>International Journal of Stroke</i> , 2012, 7, 186-187.	2.9	31
59	Does intermittent pneumatic compression reduce the risk of post stroke deep vein thrombosis? The CLOTS 3 trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 26.	0.7	9
60	Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. <i>Trials</i> , 2011, 12, 252.	0.7	38
61	Blood Biomarkers for the Diagnosis of Acute Cerebrovascular Diseases: A Prospective Cohort Study. <i>Cerebrovascular Diseases</i> , 2011, 32, 141-147.	0.8	40
62	Hoover's sign for the diagnosis of functional weakness: A prospective unblinded cohort study in patients with suspected stroke. <i>Journal of Psychosomatic Research</i> , 2011, 71, 384-386.	1.2	67
63	"Can It Read My Mind?" "What Do the Public and Experts Think of the Current (Mis)Uses of Neuroimaging?". <i>PLoS ONE</i> , 2011, 6, e25829.	1.1	22
64	The brain, the science and the media. <i>EMBO Reports</i> , 2011, 12, 630-636.	2.0	27
65	Should mechanical embolectomy devices be used in routine clinical practice?. <i>Journal of Neural Transmission</i> , 2011, 118, 1131-1138.	1.4	0
66	Association of Circulating Inflammatory Markers With Recurrent Vascular Events After Stroke. <i>Stroke</i> , 2011, 42, 10-16.	1.0	77
67	The Authors Say: "The Data Are Not So Robust because of Heterogeneity" So, How Should I Deal with This Systematic Review?. <i>Cerebrovascular Diseases</i> , 2011, 31, 615-620.	0.8	20
68	Can clinical features distinguish between immobile patients with stroke at high and low risk of deep vein thrombosis? Statistical modelling based on the CLOTS trials cohorts. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1067-1073.	0.9	24
69	Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: Report of the Therapeutics and Technology Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2011, 76, 2036-2038.	1.5	10
70	Vitamin B supplements for prevention of stroke. <i>Lancet Neurology</i> , The, 2010, 9, 842-843.	4.9	2
71	"Where are we Now with Intravenous Thrombolysis for Acute Ischaemic Stroke?". <i>International Journal of Stroke</i> , 2010, 5, 381-382.	2.9	4
72	How many Patients might Receive Thrombolytic Therapy in the Light of the ECASS-3 and IST-3 Data?. <i>International Journal of Stroke</i> , 2010, 5, 430-431.	2.9	8

#	ARTICLE	IF	CITATIONS
73	Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. British Journal of Haematology, 2010, 148, 339-340.	1.2	3
74	The Johann Jakob Wepfer Award 2010 of the European Stroke Conference to Professor Jan van Gijn. Cerebrovascular Diseases, 2010, 30, 327-329.	0.8	0
75	Carotid stenosis—surgery or stenting to prevent stroke?. Nature Reviews Neurology, 2010, 6, 647-648.	4.9	1
76	“Yes” or “No” to Routine Statins After Subarachnoid Hemorrhage to Prevent Delayed Cerebral Ischaemia, Vasospasm, and Death?. Stroke, 2010, 41, e1-2.	1.0	5
77	A telephone hotline for transient ischaemic attack and stroke: prospective audit of a model to improve rapid access to specialist stroke care. BMJ: British Medical Journal, 2010, 341, c3265-c3265.	2.4	12
78	Causes of Death by Level of Dependency at 6 Months After Ischemic Stroke in 3 Large Cohorts. Stroke, 2009, 40, 1585-1589.	1.0	50
79	Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6. PLoS Medicine, 2009, 6, e1000145.	3.9	223
80	Evidence-based practice for stroke. Lancet Neurology, The, 2009, 8, 308-309.	4.9	73
81	Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurology, The, 2009, 8, 908-917.	4.9	222
82	Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurology, The, 2009, 8, 898-907.	4.9	196
83	Blood Markers for the Prognosis of Ischemic Stroke. Stroke, 2009, 40, e380-9.	1.0	261
84	Anticoagulants for Acute Ischemic Stroke. Stroke, 2009, 40, .	1.0	9
85	The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials, 2008, 9, 37.	0.7	86
86	EPITHET—where next?. Lancet Neurology, The, 2008, 7, 570-571.	4.9	6
87	Sensible approaches for reducing clinical trial costs. Clinical Trials, 2008, 5, 75-84.	0.7	153
88	Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ: British Medical Journal, 2008, 336, 376-379.	2.4	154
89	Blood Biomarkers in the Diagnosis of Ischemic Stroke. Stroke, 2008, 39, 2902-2909.	1.0	162
90	Anticoagulants for Acute Ischemic Stroke. Chest, 2008, 134, 466.	0.4	1

#	ARTICLE	IF	CITATIONS
91	Prevention of venous thromboembolism after acute ischaemic stroke. <i>Lancet, The</i> , 2007, 370, 735-736.	6.3	7
92	Third International Stroke Trial. <i>International Journal of Stroke</i> , 2006, 1, 172-176.	2.9	56
93	Immediate Anticoagulation for Acute Stroke in Atrial Fibrillation. <i>Stroke</i> , 2006, 37, 3054-3055.	1.0	9
94	Response to Letter by Sanossian et al. <i>Stroke</i> , 2006, 37, 2661-2661.	1.0	0
95	Impact of Stroke Syndrome and Stroke Severity on the Process of Consent in the Third International Stroke Trial. <i>Cerebrovascular Diseases</i> , 2006, 21, 348-352.	0.8	34
96	Physical Methods for Preventing Deep Vein Thrombosis in Stroke. <i>Stroke</i> , 2005, 36, 1102-1103.	1.0	2
97	Follow-up by mail in clinical trials: does questionnaire length matter?. <i>Contemporary Clinical Trials</i> , 2004, 25, 31-52.	2.0	138
98	Cost-Effectiveness of Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke Assessed by a Model Based on UK NHS Costs. <i>Stroke</i> , 2004, 35, 1490-1497.	1.0	109
99	Contents of the Cochrane Library on the Organisation of Stroke Services. <i>Cerebrovascular Diseases</i> , 2003, 15, 2-4.	0.8	1
100	Full Heparin Anticoagulation Should Not Be Used in Acute Ischemic Stroke. <i>Stroke</i> , 2003, 34, 231-232.	1.0	25
101	A fainting mechanic. <i>Lancet, The</i> , 2002, 360, 305.	6.3	2
102	Systematic reviews of animal experiments. <i>Lancet, The</i> , 2002, 360, 586.	6.3	117
103	Venous Thromboembolism After Acute Stroke. <i>Stroke</i> , 2001, 32, 1443-1448.	1.0	2
104	Intravenous Unfractionated Heparin in Patients With Acute Ischemic Stroke: A Treatment to Be Used in the Context of Randomized Trials Only. <i>Stroke</i> , 2001, 32, 579-579.	1.0	9
105	Schlaganfall: Primärbehandlung. <i>Vasa - European Journal of Vascular Medicine</i> , 2001, 30, 305-310.	0.6	0
106	Indications for Early Aspirin Use in Acute Ischemic Stroke. <i>Stroke</i> , 2000, 31, 1240-1249.	1.0	567
107	Framework for design and evaluation of complex interventions to improve health. <i>BMJ: British Medical Journal</i> , 2000, 321, 694-696.	2.4	2,664
108	Antiplatelet Therapy in Acute Cerebral Ischaemia. <i>Stroke</i> , 1999, 30, 2238-2248.	1.0	4

#	ARTICLE	IF	CITATIONS
109	How Do Scores on the EuroQol Relate to Scores on the SF-36 After Stroke?. <i>Stroke</i> , 1999, 30, 2146-2151.	1.0	75
110	Hospital management of acute ischemic stroke in China. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 1997, 6, 361-367.	0.7	46
111	Antiplatelet Therapy with Aspirin in Acute Ischaemic Stroke. <i>Thrombosis and Haemostasis</i> , 1997, 78, 180-182.	1.8	10
112	Epileptic seizures after a first stroke: the Oxfordshire community stroke project. <i>BMJ: British Medical Journal</i> , 1997, 315, 1582-1587.	2.4	390
113	Is the EuroQol a Valid Measure of Health-Related Quality of Life After Stroke?. <i>Stroke</i> , 1997, 28, 1876-1882.	1.0	212
114	Can Simple Questions Assess Outcome after Stroke?. <i>Cerebrovascular Diseases</i> , 1994, 4, 314-324.	0.8	120
115	Depressive Disorders in Long-Term Survivors of Stroke. <i>British Journal of Psychiatry</i> , 1994, 164, 380-386.	1.7	109
116	Collaborative Worldwide Overviews of Randomized Trials. <i>Annals of the New York Academy of Sciences</i> , 1993, 703, 149-155.	1.8	4